Neuros Medical Secures $56M to Advance Altius Nerve Stimulation System

Neuros Medical has raised $56 million to expand U.S. commercialization of Altius, its FDA-approved implantable nerve stimulation system for chronic post-amputation pain. The Altius device delivers electrical pulses to damaged peripheral nerves, reducing phantom and residual limb pain in lower-limb amputees. In a 180-patient clinical trial, Altius users experienced fewer pain days, reduced opioid reliance, and improved quality of life. Serious device-related side effects were reported in 8% of patients.

Chronic post-amputation pain affects nearly 80% of amputees, often leading to depression and diminished well-being. Altius offers a non-opioid alternative, using a cuff electrode and a rechargeable pulse generator implanted near the affected nerve.

The funding, led by EQT Life Sciences and backed by existing investors, will help Neuros scale operations and expand access to VA and military healthcare systems. Amputations in the U.S. are increasingly linked to diabetes and vascular disease, emphasizing the broad need for effective pain solutions.

15-07-2025